Pharming Group’s resubmitted pediatric sNDA for Joenja® (leniolisib) in children aged 4–11 with APDS has been accepted by the FDA, with a PDUFA target action date of October 24, 2026. If approved, Joenja would be the first FDA-approved therapy for APDS patients under 12 years.
Written By: Kalyani Boharapi,
M.Pharm (Reg. Affairs)
Reviewed By: Pharmacally Editorial Team
Pharming Group announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) for Joenja® (leniolisib) in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). The agency assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 24, 2026. If approved, Joenja would become the first FDA-approved therapy in the United States for APDS patients under 12 years of age.
Resubmission Context
The pediatric filing follows a Complete Response Letter (CRL) issued in January 2026 and a subsequent Type A meeting in March. The FDA requested additional information on analytical methods used in production batch testing. Pharming confirmed that the resubmission addresses these manufacturing and quality control requirements. The application seeks approval for 40 mg and 50 mg twice-daily dosing in pediatric patients weighing at least 27 kg, while a separate sNDA for lower-dose regimens in children under 27 kg is planned for the second half of 2026.
Mechanism of Action and Disease Burden
Joenja is an oral, selective PI3Kδ inhibitor that targets the overactive signaling pathway responsible for APDS. The disease is caused by mutations in the PIK3CD or PIK3R1 genes, which disrupt normal immune-cell development and function. APDS is characterized by recurrent infections, lymphoproliferation, autoimmunity, and gastrointestinal complications. Although it affects only one to two people per million worldwide, diagnosis is often delayed because symptoms overlap with other primary immunodeficiencies. Untreated disease can lead to progressive complications, including chronic lung damage and lymphoma.
Clinical Evidence
The resubmission is supported by data from an open-label, multinational, single-arm Phase III study in children aged 4 to 11 years (NCT05438407). After 12 weeks of treatment, patients showed improvements in two key hallmarks of APDS: reduced lymphadenopathy and increased naïve B-cell levels, indicating correction of the underlying immune dysfunction. Benefits were observed across all dose levels and were consistent with findings previously reported in adolescent and adult APDS patients. Leniolisib also demonstrated a favorable safety profile: no severe or drug-related serious adverse events were reported, and all enrolled patients completed the 12-week treatment period.
Clinical Implications and Global Development
Chief Executive Officer Fabrice Chouraqui said FDA acceptance brings the company closer to expanding access to targeted treatment for younger children living with APDS. He emphasized the significant burden the disease places on patients and families and highlighted Pharming’s commitment to working with regulators to broaden pediatric access to leniolisib.
Joenja received FDA approval in March 2023 for APDS patients aged 12 years and older. The therapy is also approved in Europe, the United Kingdom, Japan, Australia, and Israel, while regulatory reviews continue in Canada and other markets. Beyond APDS, leniolisib is being evaluated in Phase II studies across additional primary immunodeficiencies characterized by immune dysregulation.
Reference
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.